Emerging drugs for hepatocellular carcinoma. (Q36580595)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16939386%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

review article

1 reference

title

Emerging drugs for hepatocellular carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16939386%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16939386%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Gregory J Gores

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16939386%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

language of work or name

English

0 references

publication date

1 September 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16939386%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Emerging Drugs

29 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16939386%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16939386%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16939386%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

469-487

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16939386%20AND%20SRC:MED&resulttype=core&format=json

A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.

29 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Functional genomics of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Intrinsic tumour suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Dissecting p53 tumor suppressor functions in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Kit as a human oncogenic tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Oncogenic derivatives of platelet-derived growth factor receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Successful treatment of hepatocellular carcinoma with the tyrosine kinase inhibitor imatinib in a patient with liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Self-renewal and solid tumor stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

NF-kappaB functions as a tumour promoter in inflammation-associated cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Immune pathogenesis of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Farnesyltransferase inhibitor, ABT-100, is a potent liver cancer chemopreventive agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Targeting Ras and Rho GTPases as opportunities for cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Wnt/Frizzled signaling in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Regulating the p53 system through ubiquitination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Parkin gene alterations in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Proteasome: an emerging target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Histone deacetylase inhibitors and anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Suppression of growth of hepatocellular carcinoma by sodium butyrate in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

mTOR and P70 S6 kinase expression in primary liver neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Liver transplantation and tacrolimus monotherapy for hepatocellular carcinoma with expanded criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Successful use of sirolimus in a patient with bulky ovarian metastasis of hepatocellular carcinoma after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Complete remission of postransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Potent antitumor efficacy of an E1B 55kDa-deficient adenovirus carrying murine endostatin in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Telomerase and human tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

Telomerase reverse transcriptase (hTERT) mRNA and telomerase RNA (hTR) as targets for downregulation of telomerase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.469

10.1517/14728214.11.3.469

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16939386%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16939386%20AND%20SRC:MED&resulttype=core&format=json